Holen Sie sich die Stockscreener-App
10.14
0.10%
-0.010
Handel nachbörslich:
10.14
Schlusskurs vom Vortag:
$10.15
Offen:
$10
24-Stunden-Volumen:
42,412
Relative Volume:
0.29
Marktkapitalisierung:
$246.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.20%
1M Leistung:
-34.37%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.68
$10.49
1-Wochen-Bereich:
$9.68
$11.13
52-Wochen-Spanne:
$9.68
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Firmenname
Artiva Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 267-4467
Adresse
5505 MOREHOUSE DRIVE, SAN DIEGO
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Eingeleitet | Jefferies | Buy |
| 2024-08-13 | Eingeleitet | Needham | Buy |
| 2024-08-13 | Eingeleitet | TD Cowen | Buy |
| 2024-08-13 | Eingeleitet | Wedbush | Outperform |
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Cell therapy developer Artiva refiles for a $100M IPO - MSN
Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com
Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com
Artiva Biotherapeutics appoints new board member - Investing.com
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat
Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment - AOL
Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World
Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat
Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat
Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga
Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World
Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World
Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart
July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World
VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India
Artiva: Natural Killer Cell Biotech With First Half Of 2025 Lupus Treatment Data - Seeking Alpha
Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases - MedCity News
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Artiva Biotherapeutics surges on trading debut - MSN
Public Equity Report: Artiva’s debut comes amid underwhelming IPO season - BioCentury
Artiva Biotherapeutics IPO opens at $16, priced at $12 By Investing.com - Investing.com Canada
Artiva prices $167M IPO as its AlloNK cell therapy advances - BioWorld Online
Artiva Shares Jump 30% After Upsized $167 Million US IPO - Bloomberg
Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN
Cooley, Latham Lead Biotech Firm Artiva's Upsized $167M IPO - Law360
Artiva Biotherapeutics stock in trading debut (Pending:ARTV) - Seeking Alpha
Watkins Advises on Artiva Biotherapeutics’ US$167.0 Million Initial Public Offering - Latham & Watkins LLP -
Artiva Biotherapeutics Prices 13.92M Share IPO at $12/sh - Investing.com
Artiva Biotherapeutics announces pricing of upsized $167M IPO (Pending:ARTV) - Seeking Alpha
Finanzdaten der Artiva Biotherapeutics Inc-Aktie (ARTV)
Es liegen keine Finanzdaten für Artiva Biotherapeutics Inc (ARTV) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):